A Review of Potential Harmful Interactions between Anticoagulant/Antiplatelet Agents and Chinese Herbal Medicines

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Tsai, Hsin Hui ^a,b   Lin, Hsiang Wen ^a,b,c   Lu, Ying Hung ^a   Chen, Yi Ling ^a   Mahady, Gail B ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYWARFARIN; ANGELICA SINENSIS EXTRACT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HERBACEOUS AGENT; NATURAL PRODUCT; SALVIA MILTIORRHIZA EXTRACT; TURMERIC; UNCLASSIFIED DRUG; WARFARIN;

ANGELICA SINENSIS; ARTICLE; BLEEDING; CHINESE MEDICINE; ECHINACEA; FRUIT; GINGER; GINKGO BILOBA; GINSENG; GLYCYRRHIZA URALENSIS; HERB DRUG INTERACTION; HUMAN; HYPERICUM PERFORATUM; INTERNATIONAL NORMALIZED RATIO; MATRICARIA; PHARMACODYNAMICS; PLANT ROOT; SALVIA MILTIORRHIZA;

ANTICOAGULANTS; DRUGS, CHINESE HERBAL; HEMORRHAGE; HERB-DRUG INTERACTIONS; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS;

EID: 84877333836     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064255     Document Type: Article

References (142)

1. World Health Organization (WHO) (2008). The 10 leading causes of death by broad income group. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed May 25, 2012.
2. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, et al. (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 42: 227-276.
3. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, et al. (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165: 1095-1106.
4. Dunn SP, Macaulay TE, (2011) Drug-Drug Interactions Associated with Antiplatelet Therapy. Cardiovasc Hematol Agents Med Chem 9: 231.
5. Ulbricht C, Chao W, Costa D, Rusie-Seamon E, Weissner W, et al. (2008) Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. Curr Drug Metab 9: 1063-1120.
6. Izzo AA, Di Carlo G, Borrelli F, Ernst E, (2005) Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 98: 1-14.
7. Su D, Li L, (2011) Trends in the use of complementary and alternative medicine in the United States: 2002-2007. J Health Care Poor Underserved 22: 296-310.
8. Rossler W, Lauber C, Angst J, Haker H, Gamma A, et al. (2007) The use of complementary and alternative medicine in the general population: Results from a longitudinal community study. Psychol Med 37: 73-84.
9. Ernst E, (2000) Prevalence of use of complementary/alternative medicine: a systematic review. Bull World Health Organ 78: 252-257.
10. Yeh GY, Davis RB, Phillips RS, (2006) Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol 98: 673-680.
11. Lee GBW, Charn TC, Chew ZH, Ng TP, (2004) Complementary and alternative medicine use in patients with chronic diseases in primary care is associated with perceived quality of care and cultural beliefs. Fam Pract 21: 654-660.
12. Chang LC, Huang N, Chou YJ, Lee CH, Kao FY, et al. (2008) Utilization patterns of Chinese medicine and Western medicine under the National Health Insurance Program in Taiwan, a population-based study from 1997 to 2003. BMC Health Serv Res 8: 170.
13. Lim MK, Sadarangani P, Chan HL, Heng JY, (2005) Complementary and alternative medicine use in multiracial Singapore. Complement Ther Med 13: 16-24.
14. Lai D, Chappell N, (2007) Use of Traditional Chinese Medicine by older Chinese immigrants in Canada. Fam Pract 24: 56-64.
15. Chen FN, Lee CPD, Hsieh CL, Lin CC, Chiang HM, et al. (2008) Survey on Adult Behavior and Medication of Chinese and Western Medicine-Based on the Outpatients of a Medical Center in Mid-Taiwan. J Int Chin West Med 10: 25-34.
16. Rochelle TL, Marks DF, (2010) Medical pluralism of the Chinese in London: an exploratory study. Br J Health Psychol 15: 715-728.
17. Tsai HH, Lin HW, Chien CR, Li TC (2012) Concurrent use of antiplatelets, anticoagulants, or digoxin with Chinese medications: a population-based cohort study. Eur J Clin Pharmacol DOI 10.1007/s00228-012-1359-6.
18. Alherbish A, Charrois TL, Ackman ML, Tsuyuki RT, Ezekowitz JA, (2011) The prevalence of natural health product use in patients with acute cardiovascular disease. PLoS One 6: e19623.
19. Suchard JR, Suchard MA, Steinfeldt JL, (2004) Physician knowledge of herbal toxicities and adverse herb-drug interactions. Eur J Emerg Med 11: 193-197.
20. Saw JT, Bahari MB, Ang HH, Lim YH, (2006) Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 12: 236-241.
21. Mahady GB (2001) Botanical dietary supplements: Quality, safety and efficacy. Lisse, The Netherlands: Swets & Zeitlinger Publishers.
22. Cassileth BC, Yeung KS (2003) Herb-drug interactions in oncology. Hamilton: London BC Decker Inc.
23. Ulbricht CE (2005) Natural standard herbs & supplement reference: Evidence-based clinical review. St. Louis, Mo.: Mosby/Elsevier.
24. Tatro DS (2011) Drug interaction facts. Saint Louis: Wolters Kluwer Health/Facts & Comparisons.
25. Stargrove MB, Treasure J, McKee DL (2008) Herb, nutrient, and drug interactions: Clinical implications and therapeutic strategies. St. Louis: Mosby Elsevier.
26. Philp RB (2004) Herbal-drug interactions and adverse effects: An evidence-based quick reference guide. USA: McGraw-Hill Professional.
27. Jennes F, Flaws B (2007) Herb toxicities & drug interactions: A formula approach. Boulder: Blue Poppy Press.
28. Williamson E, Driver S, Baxter K (2009) Stockley's herbal medicines interactions. London: Pharmaceutical Press.
29. Committee on Chinese Medicine and Pharmacy, Department of Health, Executive Yuan. Abstract of yearbook. http://www.ccmp.gov.tw/en/research/result.asp?relno=51&level=C. Accessed March 10, 2012.
30. Department of Health, Executive Yuan, R.O.C. (TAIWAN). Government research bulletin. http://grbsearch.stpi.narl.org.tw/GRB/. Accessed March 15, 2012.
31. Office of Dietary Supplements. Dietary Supplement Fact Sheets. http://ods.od.nih.gov/factsheets/list-all/. Accessed March 19, 2012.
32. National Center for Complementary and Alternative Medicine. Herbs at a Glance. http://nccam.nih.gov/health/herbsataglance.htm. Accessed March 20, 2012.
33. National Center for Complementary and Alternative Medicine (2010) Traditional Chinese Medicine: An Introduction. http://nccam.nih.gov/health/whatiscam/chinesemed.htm. Accessed March 1, 2012.
34. Committee on Chinese Medicine and Pharmacy (2004) Taiwan Herbal Pharmacopoeia. Taipei: Department of Health, Executive Yuan.
35. Chang HC, Tsai KU (2003) Chinese Medicinal Herbs Preparation. Taichung: China Medical University.
36. State Administration of Traditional Chinese Medicine (1999) Chinese Materia Medica. Shanghai: Shanghai scientific and Technical Publishers.
37. MICROMEDEX® 1.0 (Healthcare Series). Interaction Database. http://www.thomsonhc.com/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/A304ED/DUPLICATIONSHIELDSYNC/95C0EB/ND_PG/PRIH/ND_B/HCS/ND_P/Main/PFActionId/hcs.Interactions.FindDrugInteractions. Accessed April 15, 2012.
38. Lexicomp. Lexi-Interact Online (2012). http://www.uptodate.com/crlsql/interact/frameset.jsp.Accessed April 18, 2012.
39. Natural Medicines Comprehensive Database. Natural Product/Drug Interaction Checker. http://naturaldatabase.therapeuticresearch.com/nd/Search.aspx?s=ND&cs=&pt=7&rli=1&sh=. Accessed April 20, 2012.
40. Awang DV, Fugh-Berman A, (2002) Herbal interactions with cardiovascular drugs. J Cardiovasc Nurs 16: 64-70.
41. Bone KM, (2008) Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res 52: 764-771.
42. Borrelli F, Izzo AA, (2009) Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 11: 710-727.
43. Brazier NC, Levine MA, (2003) Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 10: 163-169.
44. Bressler R, (2005) Herb-drug interactions. Interactions between saw palmetto and prescription medications. Geriatrics 60: 32.
45. Bressler R, (2005) Herb-drug interactions: interactions between ginseng and prescription medications. Geriatrics 60: 16-17.
46. Bressler R, (2005) Herb-drug interactions. St. John's wort and prescription medications. Geriatrics 60: 21-23.
47. Bressler R, (2005) Herb-drug interactions: interactions between Ginkgo biloba and prescription medications. Geriatrics 60: 30-33.
48. Butterweck V, Derendorf H, (2008) Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet 47: 383-397.
49. Chan E, Tan M, Xin J, Sudarsanam S, Johnson DE, (2010) Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel 13: 50-65.
50. Chavez ML, Jordan MA, Chavez PI, (2006) Evidence-based drug-herbal interactions. Life Sci 78: 2146-2157.
51. Choi YH, Chin YW, Kim YG, (2011) Herb-drug interactions: focus on metabolic enzymes and transporters. Arch Pharm Res 34: 1843-1863.
52. Cohen PA, Ernst E, (2010) Safety of herbal supplements: a guide for cardiologists. Cardiovasc Ther 28: 246-253.
53. Colalto C, (2010) Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacol Res 62: 207-227.
54. Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD, (2004) Herb-drug interactions: an evidence based approach. Curr Med Chem 11: 1513-1525.
55. De Smet PAGM, Floor-Schreudering A, Bouvy ML, Wensing M, (2008) Clinical risk management of interactions between natural products and drugs. Curr Drug Metab 9: 1055-1062.
56. Di Carlo G, Borrelli F, Ernst E, Izzo AA, (2001) St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292-297.
57. Di YM, Li CG, Xue CC, Zhou S-F, (2008) Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 14: 1723-1742.
58. Ernst E, (2000) Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol 56: 523-524.
59. Ernst E, (2004) Risks of herbal medicinal products. Pharmacoepidemiol Drug Saf 13: 767-771.
60. Fugh-Berman A, (2000) Herb-drug interactions. Lancet 355: 134-138.
61. Fugh-Berman A, Ernst E, (2001) Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 52: 587-595.
62. Gardiner P, Phillips R, Shaughnessy AF, (2008) Herbal and dietary supplement - drug interactions in patients with chronic illnesses. Am Fam Physician 77: 73-78.
63. Greenblatt DJ, von Moltke LL, (2005) Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45: 127-132.
64. Greeson JM, Sanford B, Monti DA, (2001) St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 153: 402-414.
65. Haller CA, (2006) Clinical approach to adverse events and interactions related to herbal and dietary supplements. Clin Toxicol (Phila) 44: 605-610.
66. Holcomb SS, (2009) Common herb-drug interactions: what you should know. Nurse Pract 34: 21-29.
67. Hu Z, Yang X, Ho PCL, Chan SY, Heng PWS, et al. (2005) Herb-drug interactions: a literature review. Drugs 65: 1239-1282.
68. Huang S-M, Lesko LJ, (2004) Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? J Clin Pharmacol 44: 559-569.
69. Izzo AA, (2005) Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 19: 1-16.
70. Izzo AA, Ernst E, (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61: 2163-2175.
71. Izzo AA, Ernst E, (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69: 1777-1798.
72. Javed F, Golagani A, Sharp H, (2008) Potential effects of herbal medicines and nutritional supplements on coagulation in ENT practice. J Laryngol Otol 122: 116-119.
73. Ko RJ, (2004) A U.S. perspective on the adverse reactions from traditional Chinese medicines. J Chin Med Assoc 67: 109-116.
74. Kuhn MA (2002) Herbal remedies: drug-herb interactions. Crit Care Nurse 22: 22-28, 30, 32.
75. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V, (2006) Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62: 225-233.
76. Markowitz JS, DeVane CL, (2001) The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum). Psychopharmacol Bull 35: 53-64.
77. McFadden R, Peterson N, (2011) Interactions between drugs and four common medicinal herbs. Nurs Stand 25: 65-68.
78. Mills E, Wu P, Johnston BC, Gallicano K, Clarke M, et al. (2005) Natural health product-drug interactions: a systematic review of clinical trials. Ther Drug Monit 27: 549-557.
79. Norred CL, Brinker F, (2001) Potential coagulation effects of preoperative complementary and alternative medicines. Altern Ther Health Med 7: 58-67.
80. Nutescu E, Chuatrisorn I, Hellenbart E, (2011) Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis 31: 326-343.
81. Nutescu EA, Shapiro NL, Ibrahim S, West P, (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5: 433-451.
82. Ohnishi N, Yokoyama T, (2004) Interactions between medicines and functional foods or dietary supplements. Keio J Med 53: 137-150.
83. Pal D, Mitra AK, (2006) MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78: 2131-2145.
84. Poppenga RH, (2002) Herbal medicine: potential for intoxication and interactions with conventional drugs. Clin Tech Small Anim Pract 17: 6-18.
85. Samuels N, (2005) Herbal remedies and anticoagulant therapy. Thromb Haemost 93: 3-7.
86. Singh YN, (2005) Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100: 108-113.
87. Skalli S, Zaid A, Soulaymani R, (2007) Drug interactions with herbal medicines. Ther Drug Monit 29: 679-686.
88. Tachjian A, Maria V, Jahangir A, (2010) Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 55: 515-525.
89. Tirona RG, Bailey DG, (2006) Herbal product-drug interactions mediated by induction. Br J Clin Pharmacol 61: 677-681.
90. Tomlinson B, Hu M, Lee VWY, (2008) In vivo assessment of herb-drug interactions: possible utility of a pharmacogenetic approach? Mol Nutr Food Res 52: 799-809.
91. Ueng YF, Chen RM, (2004) The role of cytochrome P450 in herb-drug interactions. Curr Pharmacogenomics Person Med 2: 209-218.
92. Venkataramanan R, Komoroski B, Strom S, (2006) In vitro and in vivo assessment of herb drug interactions. Life Sci 78: 2105-2115.
93. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H, (2006) The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 62: 512-526.
94. Williamson EM, (2003) Drug interactions between herbal and prescription medicines. Drug Saf 26: 1075-1092.
95. Williamson EM, (2005) Interactions between herbal and conventional medicines. Expert Opin Drug Saf 4: 355-378.
96. Wittkowsky AK, (2008) Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 25: 72-77.
97. Woodward KN, (2005) The potential impact of the use of homeopathic and herbal remedies on monitoring the safety of prescription products. Hum Exp Toxicol 24: 219-233.
98. Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF, (2006) Drug-herb interactions: Eliminating toxicity with hard drug design. Curr Pharm Des 12: 4649-4664.
99. Zhou L, Zuo Z, Chow MS, (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45: 1345-1359.
100. Zhou S, Chan E, Pan S-Q, Huang M, Lee EJD, (2004) Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 18: 262-276.
101. Zhou S, Gao Y, Jiang W, Huang M, Xu A, et al. (2003) Interactions of herbs with cytochrome P450. Drug Metab Rev 35: 35-98.
102. Zhou S-F, Zhou Z-W, Li C-G, Chen X, Yu X, et al. (2007) Identification of drugs that interact with herbs in drug development. Drug Discov Today 12: 664-673.
103. Mao XQ, Xie HT, Zhou HH, (2007) MDR-and CYP3A4-mediated drug-herbal Interactions. Chinese Journal of Clinical Pharmacology and Therapeutics 12: 728-734.
104. Wang TY, (2011) Outcomes Influenced by Drug Interactions. The Journal of Long Term Care 15: 24-32.
105. Wang YY, (2003) Interactions between warfarin and other anticoagulant agents or herbal medicine. The Journal of Taiwan Pharmacy 19: 5-10.
106. Li JY, Shih HJ, Tsai ML, (2008) Interactions between warfarin and chinese herbal medicine. The Journal of Taiwan Pharmacy 24: 135-142.
107. Lin JJ, (2003) Interactions between Herbal and Conventional Therapies: Focus on Ginseng and Ginkgo Biloba. Show Chwan Medical Journal 4: 1-4.
108. Chen FP, Zhong MX, Huang XZ, (2011) The whole aspects of interaction between traditional Chinese medicine and western medicine. Family Medicine & Primary Medical Care 26: 168-176.
109. Chen JF, Hu YJ, Miao CY, (2007) Advancement of pharmacokinetic studies on Chinese herbal medicine-synthetic drug interactions. Clin J Clin Pharmacol Ther 12: 1348-1353.
110. Peng B, Li JR, He R (2010) The research status of herb-drug interactions. World Science and Technology-Modernization of Traditional Chinese Medicine. doi: 10.3969/j.issn.1674-3849.2010.02.024.
111. Tsai CH, Lu CY, (2009) Analysis on the interaction of warfarinand ginseng. Taipei Journal of Chinese Medicine 15: 98-109.
112. Lai YC, Chen YL, Lai JS, (2007) Toxicity of Chinese Herbal Medicine and drug-herb Interactions. The Chung Shan Medical Journal 18: 343-357.
113. Kuo YH, Lin YL, Don MJ, Chen RM, Ueng YF, (2006) Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J Pharm Pharmacol 58: 521-527.
114. Li Y, Wang N, (2010) Antithrombotic effects of Danggui, Honghua and potential drug interaction with clopidogrel. J Ethnopharmacol 128: 623-628.
115. Makino T, Wakushima H, Okamoto T, Okukubo Y, Deguchi Y, et al. (2002) Pharmacokinetic interactions between warfarin and kangen-karyu, a Chinese traditional herbal medicine, and their synergistic action. J Ethnopharmacol 82: 35-40.
116. Wu WWP, Yeung JHK, (2010) Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo. Phytomedicine 17: 219-226.
117. Abdul MI, Jiang X, Williams KM, Day RO, Roufogalis BD, et al. (2010) Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. Br J Clin Pharmacol 69: 508-515.
118. Jiang X, Blair EYL, McLachlan AJ, (2006) Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 46: 1370-1378.
119. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, et al. (2004) Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 57: 592-599.
120. Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, et al. (2004) Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial. Ann Intern Med 141: 23-27.
121. Blalock SJ, Gregory PJ, Patel RA, Norton LL, Callahan LF, et al. (2009) Factors associated with potential medication-herb/natural product interactions in a rural community. Altern Ther Health Med 15: 26-34.
122. Bush TM, Rayburn KS, Holloway SW, Sanchez-Yamamoto DS, Allen BL, et al. (2007) Adverse interactions between herbal and dietary substances and prescription medications: a clinical survey. Altern Ther Health Med 13: 30-35.
123. Canter PH, Ernst E, (2004) Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs Aging 21: 597-605.
124. Chan ALF, Leung HWC, Wu J-W, Chien T-W, (2011) Risk of hemorrhage associated with co-prescriptions for Ginkgo biloba and antiplatelet or anticoagulant drugs. J Altern Complement Med 17: 513-517.
125. Chan H-T, So L-T, Li S-W, Siu C-W, Lau C-P, et al. (2011) Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. J Cardiovasc Pharmacol 58: 87-90.
126. Charrois TL, Hill RL, Vu D, Foster BC, Boon HS, et al. (2007) Community identification of natural health product-drug interactions. Ann Pharmacother 41: 1124-1129.
127. Clauson KA, Santamarina ML, Rutledge JC, (2008) Clinically relevant safety issues associated with St. John's wort product labels. BMC Complement Altern Med 8: 42.
128. Dergal JM, Gold JL, Laxer DA, Lee MSW, Binns MA, et al. (2002) Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging 19: 879-886.
129. Goldman RD, Rogovik AL, Lai D, Vohra S, (2008) Potential interactions of drug-natural health products and natural health products-natural health products among children. J Pediatr 152: 521-526.
130. Rogers EA, Gough JE, Brewer KL, (2001) Are emergency department patients at risk for herb-drug interactions? Acad Emerg Med 8: 932-934.
131. Segal R, Pilote L, (2006) Warfarin interaction with Matricaria chamomilla. CMAJ 174: 1281-1282.
132. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C, (2007) Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 27: 1237-1247.
133. Su Q, Li Y, (2010) Interaction between warfarin and the herbal product shengmai-yin: A case report of intracerebral hematoma. Yonsei Med J 51: 793-796.
134. Lai JN, (2010) Causal inference of bleeding complications in patients with warfarin treatment in Taiwan - a eleven year follow up study. Yearbook of Chinese Medicine and Pharmacy 28: 291-388.
135. Al Faraj S, (2005) Antagonism of the anticoagulant effect of warfarin caused by the use of Commiphora molmol as a herbal medication: a case report. Ann Trop Med Parasitol 99: 219-220.
136. Yamashita H, Tsukayama H, Sugishita C, (2002) Popularity of complementary and alternative medicine in Japan: a telephone survey. Complement Ther Med 10: 84-93.
137. Hsieh SC, Lai JN, Lee CF, Hu FC, Tseng WL, et al. (2008) The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database. Pharmacoepidemiol Drug Saf 17: 609-619.
138. Mousa SA, (2010) Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol 663: 229-240.
139. Xu G, Zhao W, Zhou Z, Zhang R, Zhu W, et al. (2009) Danshen extracts decrease blood C reactive protein and prevent ischemic stroke recurrence: A controlled pilot study. Phytother Res 23: 1721-1725.
140. Zhu YF, Luo HM, Deng ZL, Fu DY, Yao W, et al. (2012) Effects of the Chinese patent medicine, Honghua injection, on platelet glycoprotein Tib/Ufa receptors in patients with acute coronary syndrome: A randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 10: 318-323.
141. Clauson KA, Peak AS, Marsh WA, DiScala S, Bellinger RR, (2008) Clinical decision support tools: focus on dietary supplement databases. Altern Ther Health Med 14: 36-40.
142. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, et al. (2004) Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 44: 136-141.